Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 88pembrolizumab 77Pemetrexed 65Cisplatin 56Paclitaxel 33Docetaxel 31durvalumab 28atezolizumab 28Nivolumab 28Specimen Handling 25Magnetic Resonance Spectroscopy 20Gemcitabine 19osimertinib 18130-nm albumin-bound paclitaxel 18Etoposide 17Radiotherapy 14Cetuximab 14Platinum 12Taxes 11Immunoglobulin G 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Ipilimumab 9Disulfides 9Bevacizumab 9amivantamab 8Topotecan 8fludarabine 7Ramucirumab 7Radiosurgery 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gefitinib × Thoracic × 30 days × Clear all
NCT00238628 2026-06-04

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Stanford University

Phase 1/2 Completed
6 enrolled
Thoracic

Lung Neoplasms

NCT04248829 2026-05-28

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Yuhan Corporation

Phase 3 Completed
393 enrolled 13 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡